Axon Enterprise - AXON Stock Forecast, Price & News

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness, including streamlined investigative workflows. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Axon Enterprise Price Performance

Shares of AXON Stock traded up $5.39 during trading hours on Friday, reaching $129.49. The company had a trading volume of 477,184 shares, compared to its average volume of 309,287. Axon Enterprise has a 12-month low of $82.49 and a 12-month high of $209.00. The company has a market capitalization of $9.20 billion, a price-to-earnings ratio of 66.41 and a beta of 0.66. The stock has a fifty day moving average of $98.96 and a 200-day moving average of $112.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.18 and a current ratio of 2.70.

Axon Enterprise (NASDAQ:AXON - Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.05. Axon Enterprise had a net margin of 14.20% and a return on equity of 12.57%. The firm had revenue of $285.61 million for the quarter, compared to analysts' expectations of $258.96 million. During the same quarter in the previous year, the company posted ($0.72) EPS. The company's revenue was up 30.5% compared to the same quarter last year. On average, equities analysts anticipate that Axon Enterprise will post 1.46 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. Northland Securities dropped their price target on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. Credit Suisse Group lifted their price objective on shares of Axon Enterprise from $134.00 to $142.00 and gave the company an "outperform" rating in a research note on Wednesday. Morgan Stanley lowered shares of Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 price target on the stock. in a report on Monday, May 23rd. StockNews.com upgraded Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Finally, JMP Securities reissued a "buy" rating and set a $195.00 price target on shares of Axon Enterprise in a report on Wednesday, June 1st. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

Insider Transactions at Axon Enterprise

In related news, Director Mark W. Kroll sold 3,159 shares of the company's stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the transaction, the director now directly owns 13,691 shares in the company, valued at $1,407,708.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.90% of the company's stock.